<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Inhibitors | Clinical Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Overview of Coagulation Inhibitors  Definition: Substances that interfere with the normal function of coagulation factors, leading to impaired thrombin generation and an increased risk of bleeding...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Inhibitors | Clinical Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="Overview of Coagulation Inhibitors  Definition: Substances that interfere with the normal function of coagulation factors, leading to impaired thrombin generation and an increased risk of bleeding...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Inhibitors | Clinical Hematology">
<meta name="twitter:description" content="Overview of Coagulation Inhibitors  Definition: Substances that interfere with the normal function of coagulation factors, leading to impaired thrombin generation and an increased risk of bleeding...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Clinical Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="" href="aml.html">AML</a></li>
<li><a class="" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="" href="plasma-cell.html">Plasma Cell</a></li>
<li class="book-part">Platelets</li>
<li><a class="" href="plt-production.html">PLT Production</a></li>
<li><a class="" href="plt-function.html">PLT Function</a></li>
<li><a class="" href="plt-destruction.html">PLT Destruction</a></li>
<li><a class="" href="quantitative.html">Quantitative</a></li>
<li><a class="" href="thrombocytopenia-1.html">Thrombocytopenia</a></li>
<li><a class="" href="destruction.html">Destruction</a></li>
<li><a class="" href="production.html">Production</a></li>
<li><a class="" href="pseudo.html">Pseudo</a></li>
<li><a class="" href="thrombocytosis.html">Thrombocytosis</a></li>
<li><a class="" href="qualitative.html">Qualitative</a></li>
<li><a class="" href="von-willebrand.html">von Willebrand</a></li>
<li><a class="" href="bernard-soulier.html">Bernard-Soulier</a></li>
<li><a class="" href="glanzmann.html">Glanzmann</a></li>
<li class="book-part">Hemostasis</li>
<li><a class="" href="coagulation-pathways.html">Coagulation Pathways</a></li>
<li><a class="" href="fibrinolytic-pathways.html">Fibrinolytic Pathways</a></li>
<li><a class="" href="vascular-system.html">Vascular System</a></li>
<li><a class="" href="disorders.html">Disorders</a></li>
<li><a class="" href="factor-deficiencies.html">Factor Deficiencies</a></li>
<li><a class="" href="hereditary.html">Hereditary</a></li>
<li><a class="" href="acquired.html">Acquired</a></li>
<li><a class="active" href="inhibitors.html">Inhibitors</a></li>
<li><a class="" href="fibrinolytic.html">Fibrinolytic</a></li>
<li><a class="" href="thrombophilia.html">Thrombophilia</a></li>
<li><a class="" href="dic.html">DIC</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Hematology">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="inhibitors" class="section level1 unnumbered">
<h1>Inhibitors<a class="anchor" aria-label="anchor" href="#inhibitors"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-coagulation-inhibitors" class="section level2 unnumbered">
<h2>
<strong>Overview of Coagulation Inhibitors</strong><a class="anchor" aria-label="anchor" href="#overview-of-coagulation-inhibitors"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> Substances that interfere with the normal function of coagulation factors, leading to impaired thrombin generation and an increased risk of bleeding or, in some cases, thrombosis</li>
<li>
<strong>Classification:</strong>
<ul>
<li>Acquired Inhibitors: Antibodies (usually IgG) that develop against specific coagulation factors or phospholipid-binding proteins</li>
<li>Congenital Inhibitors: Rare, inherited deficiencies of natural anticoagulant proteins (Protein C, Protein S, Antithrombin). These are typically categorized as hypercoagulable states rather than factor deficiencies</li>
</ul>
</li>
<li>
<strong>Key Features:</strong>
<ul>
<li>Prolonged clotting time (PT and/or aPTT) that does not correct upon mixing with normal plasma (demonstrates the presence of an inhibitor)</li>
<li>May target specific coagulation factors or phospholipid-binding proteins</li>
<li>Clinical manifestations range from bleeding to thrombosis, depending on the specific inhibitor and underlying mechanism</li>
</ul>
</li>
</ul>
</div>
<div id="acquired-coagulation-inhibitors" class="section level2 unnumbered">
<h2>
<strong>Acquired Coagulation Inhibitors</strong><a class="anchor" aria-label="anchor" href="#acquired-coagulation-inhibitors"><i class="fas fa-link"></i></a>
</h2>
<p>These are antibodies that develop against coagulation factors or phospholipid-binding proteins, interfering with their function</p>
<ul>
<li>
<p><strong>Factor VIII Inhibitors (Acquired Hemophilia A):</strong></p>
<ul>
<li>
<strong>Definition:</strong> Autoantibodies (usually IgG) that develop against Factor VIII (FVIII), leading to FVIII deficiency and a bleeding disorder</li>
<li>
<strong>Etiology:</strong>
<ul>
<li>Idiopathic (most common)</li>
<li>Associated with:
<ul>
<li>Autoimmune disorders (e.g., SLE, rheumatoid arthritis)</li>
<li>Pregnancy</li>
<li>Malignancies</li>
<li>Medications (e.g., penicillin, sulfonamides)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Autoantibodies bind to FVIII and neutralize its activity or accelerate its clearance from the circulation</li>
<li>Leads to impaired thrombin generation and increased risk of bleeding</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Bleeding manifestations similar to hemophilia A
<ul>
<li>Easy bruising</li>
<li>Prolonged bleeding after cuts or surgery</li>
<li>Nosebleeds</li>
<li>Hemarthrosis (bleeding into joints) - less common than in inherited hemophilia A</li>
<li>Intracranial hemorrhage (rare but life-threatening)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC: Normal platelet count</li>
<li>Prothrombin Time (PT): Normal</li>
<li>Activated Partial Thromboplastin Time (aPTT): Prolonged</li>
<li>Mixing Study: aPTT <em>does not</em> correct upon mixing with normal plasma (demonstrates the presence of an inhibitor)</li>
<li>Factor VIII Assay: Decreased FVIII activity level</li>
<li>Factor VIII Inhibitor Assay (Bethesda Assay or Nijmegen-Bethesda Assay): Measures the titer (concentration) of the FVIII inhibitor
<ul>
<li>The Bethesda titer is expressed in Bethesda Units (BU)</li>
<li>One BU is defined as the amount of inhibitor that neutralizes 50% of FVIII in normal plasma</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Control of Bleeding Episodes:
<ul>
<li>Bypassing agents:
<ul>
<li>Activated prothrombin complex concentrates (aPCCs)</li>
<li>Recombinant Factor VIIa (rFVIIa)</li>
</ul>
</li>
<li>These agents promote thrombin generation independently of FVIII</li>
</ul>
</li>
<li>Eradication of the Inhibitor:
<ul>
<li>Immunosuppressive Therapy:
<ul>
<li>Corticosteroids (e.g., prednisone)</li>
<li>Cyclophosphamide</li>
<li>Rituximab (anti-CD20 antibody)</li>
</ul>
</li>
<li>Immune Tolerance Induction (ITI): High-dose FVIII infusions combined with immunosuppressive therapy</li>
</ul>
</li>
<li>Avoid FVIII Concentrates (unless necessary to control bleeding)
<ul>
<li>Repeated exposure to FVIII can boost the inhibitor titer</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Lupus Anticoagulant (LA):</strong></p>
<ul>
<li>
<strong>Definition:</strong> Autoantibodies that bind to phospholipids and phospholipid-binding proteins, interfering with phospholipid-dependent coagulation assays in vitro</li>
<li>
<strong>Etiology:</strong>
<ul>
<li>Primary (idiopathic)</li>
<li>Secondary: Associated with:
<ul>
<li>Autoimmune disorders (e.g., SLE)</li>
<li>Infections</li>
<li>Medications</li>
<li>Malignancies</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Antibodies bind to phospholipids and phospholipid-binding proteins (e.g., prothrombin, β2-glycoprotein I)</li>
<li>Interferes with the assembly of coagulation complexes on phospholipid surfaces <em>in vitro</em>, leading to prolonged clotting times</li>
<li>In vivo, the LA can promote thrombosis through complex mechanisms involving:
<ul>
<li>Activation of endothelial cells and platelets</li>
<li>Decreased production of prostacyclin</li>
<li>Inhibition of natural anticoagulant pathways</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Paradoxical: Despite prolonging clotting times in vitro, LA is associated with an increased risk of thrombosis (both arterial and venous)</li>
<li>Thrombotic events:
<ul>
<li>Deep vein thrombosis (DVT)</li>
<li>Pulmonary embolism (PE)</li>
<li>Stroke</li>
<li>Recurrent pregnancy loss</li>
</ul>
</li>
<li>May be asymptomatic</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Screening Test:
<ul>
<li>Prolonged aPTT: Most common finding, but PT may also be prolonged in some cases</li>
</ul>
</li>
<li>Mixing Study:
<ul>
<li>aPTT <em>does not</em> correct upon mixing with normal plasma (demonstrates the presence of an inhibitor)</li>
</ul>
</li>
<li>Confirmatory Tests:
<ul>
<li>Phospholipid-Dependent Coagulation Assays:
<ul>
<li>Dilute Russell’s viper venom time (dRVVT): Prolonged and does not correct with the addition of phospholipid</li>
<li>Silica Clotting Time (SCT): Prolonged and does not correct with the addition of phospholipid</li>
</ul>
</li>
<li>Hexagonal Phase Phospholipid Neutralization Assay:
<ul>
<li>Demonstrates that the prolonged clotting time is due to a phospholipid-dependent inhibitor</li>
<li>Clotting time corrects when hexagonal phase phospholipids are added to the test system</li>
</ul>
</li>
</ul>
</li>
<li>Anticardiolipin Antibodies and Anti-β2 Glycoprotein I Antibodies:
<ul>
<li>Often present, but not required for the diagnosis of LA</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Anticoagulation:
<ul>
<li>Warfarin (Coumadin)</li>
<li>Direct oral anticoagulants (DOACs) may be used in some cases, but there is less data on their effectiveness in patients with LA</li>
<li>The intensity and duration of anticoagulation depend on the severity of the thrombosis and the presence of other risk factors</li>
</ul>
</li>
<li>Antiplatelet Therapy:
<ul>
<li>Aspirin may be used in some patients to reduce the risk of arterial thrombosis</li>
</ul>
</li>
<li>Management of Obstetric Complications:
<ul>
<li>Low-dose aspirin and prophylactic heparin during pregnancy to prevent recurrent pregnancy loss</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p><strong>Factor V Inhibitors</strong></p>
<ul>
<li>Very rare, but when it happens results in prolonged PT and PTT</li>
</ul>
</li>
</ul>
</div>
<div id="congenital-inherited-coagulation-inhibitor-deficiencies" class="section level2 unnumbered">
<h2>
<strong>Congenital (Inherited) Coagulation Inhibitor Deficiencies</strong><a class="anchor" aria-label="anchor" href="#congenital-inherited-coagulation-inhibitor-deficiencies"><i class="fas fa-link"></i></a>
</h2>
<p>These are better classified as hypercoagulable states</p>
<ul>
<li>Protein C Deficiency</li>
<li>Protein S Deficiency</li>
<li>Antithrombin Deficiency</li>
</ul>
</div>
<div id="key-laboratory-tests-for-coagulation-inhibitors" class="section level2 unnumbered">
<h2>
<strong>Key Laboratory Tests for Coagulation Inhibitors</strong><a class="anchor" aria-label="anchor" href="#key-laboratory-tests-for-coagulation-inhibitors"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Prothrombin Time (PT):</strong> Measures the function of the extrinsic and common pathways</li>
<li>
<strong>Activated Partial Thromboplastin Time (aPTT):</strong> Measures the function of the intrinsic and common pathways</li>
<li>
<strong>Mixing Studies:</strong> To differentiate factor deficiencies from factor inhibitors</li>
<li>
<strong>Factor Assays:</strong> To measure the activity of specific coagulation factors</li>
<li>
<strong>Factor Inhibitor Assays:</strong> To detect and quantify factor inhibitors</li>
<li>
<strong>Lupus Anticoagulant Testing:</strong>
<ul>
<li>Dilute Russell’s viper venom time (dRVVT)</li>
<li>Silica Clotting Time (SCT)</li>
<li>Hexagonal Phase Phospholipid Neutralization Assay</li>
</ul>
</li>
<li><strong>Anticardiolipin and Anti-β2 Glycoprotein I Antibody Assays</strong></li>
<li>
<strong>Genetic Testing:</strong> For inherited thrombophilia mutations</li>
</ul>
</div>
<div id="key-terms-52" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-52"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Coagulation Inhibitor:</strong> An antibody that interferes with the function of a coagulation factor</li>
<li>
<strong>Lupus Anticoagulant (LA):</strong> An antibody that binds to phospholipids and proteins associated with the cell membrane</li>
<li>
<strong>Mixing Study:</strong> A test to differentiate factor deficiencies from factor inhibitors</li>
<li>
<strong>Bethesda Assay:</strong> A method for quantifying factor VIII inhibitors</li>
<li>
<strong>Thrombosis:</strong> Formation of a blood clot inside a blood vessel</li>
<li>
<strong>Antiphospholipid Syndrome (APS):</strong> An autoimmune disorder characterized by thrombosis, pregnancy morbidity, and the presence of antiphospholipid antibodies (including lupus anticoagulant, anticardiolipin antibodies, and anti-β2 glycoprotein I antibodies)</li>
</ul>
</div>
</div>
  <div class="chapter-nav">
<div class="prev"><a href="acquired.html">Acquired</a></div>
<div class="next"><a href="fibrinolytic.html">Fibrinolytic</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#inhibitors">Inhibitors</a></li>
<li><a class="nav-link" href="#overview-of-coagulation-inhibitors">Overview of Coagulation Inhibitors</a></li>
<li><a class="nav-link" href="#acquired-coagulation-inhibitors">Acquired Coagulation Inhibitors</a></li>
<li><a class="nav-link" href="#congenital-inherited-coagulation-inhibitor-deficiencies">Congenital (Inherited) Coagulation Inhibitor Deficiencies</a></li>
<li><a class="nav-link" href="#key-laboratory-tests-for-coagulation-inhibitors">Key Laboratory Tests for Coagulation Inhibitors</a></li>
<li><a class="nav-link" href="#key-terms-52">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Hematology/blob/main/04-08-hemostasis-inhibitors.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Hematology/edit/main/04-08-hemostasis-inhibitors.Rmd">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-02-20 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
